Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial

Background: To determine the clinical activity and safety of Chinese herbal medicine (CHM) combined with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) in patients with advanced pulmonary adenocarcinoma (ADC) and the ability of CHM combined with EGFR-TKI to activate EGFR muta...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Lijing, Xu, Jianfang, Sun, Jianli, Chen, Zhiwei, Gong, Yabin, Bi, Ling, Lu, Yan, Yao, Jialin, Zhu, Weirong, Hou, Aihua, Feng, Gaohua, Jia, Yingjie, Shen, Weisheng, Li, Yongjian, Zhang, Ziwen, Chen, Peiqi, Xu, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614728/
https://www.ncbi.nlm.nih.gov/pubmed/31333456
http://dx.doi.org/10.3389/fphar.2019.00732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6614728/
https://www.ncbi.nlm.nih.gov/pubmed/31333456
http://dx.doi.org/10.3389/fphar.2019.00732

Ejemplares similares